Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2009

01-03-2009 | HEPATOBILIARY AND PANCREATIC TUMORS

Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma

Authors: Ki Hun Kim, MD, PhD, Sung Gyu Lee, MD, PhD, Eun Hwa Park, MD, Shin Hwang, MD, PhD, Chul Soo Ahn, MD, PhD, Deok Bog Moon, MD, PhD, Tae Yong Ha, MD, PhD, Gi Won Song, MD, Dong Hwan Jung, MD, PhD, Kang Mo Kim, MD, PhD, Young Suk Lim, MD, PhD, Han Chu Lee, MD, PhD, Young Hwa Chung, MD, PhD, Yung Sang Lee, MD, PhD, Dong Jin Suh, MD, PhD

Published in: Annals of Surgical Oncology | Issue 3/2009

Login to get access

Abstract

Background

Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types. We evaluated the effectiveness of surgical treatment and factors related to survival and recurrence.

Patients and Methods

Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor. Their medical records were retrospectively reviewed.

Results

Disease-free survival rates at 6 months, 1 year, and 3 years were 51.1%, 38.3%, and 25.6%, respectively. Univariate analysis showed that CA 19–9 above 37 U/ml was predictive of low overall survival (P = .03) and that TNM stage was significantly associated with disease-free survival (P = .04).

Conclusions

Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates. High CA 19–9 level was associated with poorer survival, suggesting that the cholangiocarcinoma portion may be a major determining factor for patient prognosis. Aggressive surgical treatment, including lymph node dissection, may improve survival in patients suspected of or diagnosed with these tumors.
Literature
1.
Goodman ZD, Ishak KG, Langloss JM, et al. Combined hepatocellular-cholangiocarcinoma. A histologic and immunohistochemical study. Cancer. 1985;55:124–5.PubMedCrossRef
2.
Gibson JB. Histological typing of the liver. International histological classification of tumors. No. 20. Geneva: WHO; 1978. p. 19–30.
3.
Ishak KG, Anthony PP, Sobin LH. Histological typing of the liver. International histological classification of tumors. WHO. 2nd ed. Hong Kong: Springer-Verlag; 1994.
4.
The Liver Cancer Study Group of Japan. Primary liver cancer in Japan. Fourteenth National Primary Liver Cancer Tracking Survey Report (1996–1997) (in Japanese). Kyoto: Shinkou; 2000.
5.
Ng IO, Shek TW, Nicholls J, et al. Combined hepatocellular-cholangiocarcinoma: a clinicopathological study. J Gastroenterol Hepatol. 1998;13:34–40.PubMedCrossRef
6.
Allen RA, Lisa JR. Combined liver cell and bile duct carcinoma. Am J Pathol. 1949;25:647–55.PubMed
7.
Yamaoka Y, Arii S, Okita K, et al., Liver Cancer Study Group of Japan. Survey and follow-up study of primary liver cancer in Japan. Report 13. Acta Hepatol Jpn. 1999;40:288–300.
8.
Maeda T, Adachi E, Kajiyama K, et al. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analysis of clinicopathologic features. Hum Pathol. 1995;26:956–64.PubMedCrossRef
9.
Koh KC, Lee H, Choi MS, et al. Clinicopathologic features and prognosis of combined hepatocellular cholangiocarcinoma. Am J Surg. 2005;189:120–5.PubMedCrossRef
10.
Jarnagin WR, Weber S, Tickoo SK, et al. Combined hepatocellular and cholangiocarcinoma: demographic, clinical, and prognostic factors. Cancer. 2002;94:2040–6.PubMedCrossRef
11.
Kawasaki S, Makuuchi M, Miyagawa S, et al. Radical operation after portal embolization for tumor of hilar bile duct. J Am Coll Surg. 1994;178:480–6.PubMed
12.
Taguchi J, Nakashima O, Tanaka M, et al. A clinicopathological study on combined hepatocellular and cholangiocarcinoma. J Gastroenterol Hepatol. 1996; 11:758–64.PubMedCrossRef
13.
Liu CL, Fan ST, Lo CM, et al. Hepatic resection for combined hepatocellular and cholangiocarcinoma. Arch Surg. 2003;138:86–90.PubMedCrossRef
14.
Edmondson H, Peters RL. Neoplasms of liver. In: Schiff L, Schoff E, editors. Disease of the Liver. 5th ed. Philadelphia: Lippincott; 1982.
15.
Kojiro M. Pathomorphology of advanced hepatocellular carcinoma. In: Tobe T, et al., editors. Primary liver cancer in Japan. Tokyo: Springer-Verlag; 1992. p. 31–7.
16.
Imai Y, Oda H, Arai M, et al. Mutational analysis of the p53 and K-ras genes and allelotype study of the Rb-1 gene for investigating the pathogenesis of combined hapatocellular-cholangiocellular carcinomas. Jpn J Cancer Res. 1996;87:1056–62.PubMed
17.
Yano Y, Yamamoto J, Kosuge T, et al. Combined hepatocellular and cholangiocarcinoma: a clinicopathologic study of 26 resected cases. Jpn J Clin Oncol. 2003;33:283–7.PubMedCrossRef
18.
Tomimatsu M, Ishiguro N, Taniai M, et al. Hepatitis C virus antibody in patients with primary liver cancer (hepatocellular carcinoma, cholangiocarcinoma, and combined hepatocellular-cholangiocarcinoma) in Japan. Cancer. 1993;72:683–8.PubMedCrossRef
19.
Asayama Y, Taguchi Ki K, Aishima Si S, et al. The mode of tumour progression in combined hepatocellular carcinoma and cholangiocarcinoma: an immunohistochemical analysis of E-cadherin, alpha-catenin and beta-catenin. Liver Int. 2002;22:43–50.CrossRef
20.
Lee WS, Lee KW, Heo JS, et al. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Surg Today. 2006;36:892–7.PubMedCrossRef
21.
Uenishi T, Hirohashi K, Shuto T, et al. Surgery for mixed hepatocellular and cholangiocellular carcinoma. Hepatogastroenterology. 2000;47:832–4.PubMed
22.
Albacete RA, Matthews MJ, Saini N. Portal vein thromboses in malignant hepatoma. Ann Intern Med. 1967; 67:337–48.PubMed
23.
24.
Nakamura S, Suzuki S, Sakaguchi T, et al. Surgical treatment of patients with mixed hepatocellular carcinoma and cholangiocarcinoma. Cancer. 1996;78:1671–6.PubMedCrossRef
25.
Tickoo SK, Zee SY, Obiekwe S, et al. Combined hepatocellular-cholangiocarcinoma: a histopathologic, immunohistochemical, and in situ hybridization study. Am J Surg Pathol. 2002;26:989–97.PubMedCrossRef
26.
Kosuge T, Makuuchi M, Takayama T, et al. Long-term results after resection of hepatocellular carcinoma: experience of 480 cases. Hepatogastroenterology. 1993;40:328–32.PubMed
27.
Yamamoto J, Kosuge T, Takayama T, et al. Recurrence of hepatocellular carcinoma after surgery. Br J Surg. 1996;83:1219–22.PubMedCrossRef
28.
Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg. 1999;229:790–800.PubMedCrossRef
29.
Nishie A, Yoshimitsu K, Asayama Y, et al. Detection of combined hepatocellular and cholangiocarcinomas on enhanced CT: comparison with histologic findings. AJR Am J Roentgenol. 2005;184:1157–62.PubMed
Metadata
Title
Surgical Treatments and Prognoses of Patients with Combined Hepatocellular Carcinoma and Cholangiocarcinoma
Authors
Ki Hun Kim, MD, PhD
Sung Gyu Lee, MD, PhD
Eun Hwa Park, MD
Shin Hwang, MD, PhD
Chul Soo Ahn, MD, PhD
Deok Bog Moon, MD, PhD
Tae Yong Ha, MD, PhD
Gi Won Song, MD
Dong Hwan Jung, MD, PhD
Kang Mo Kim, MD, PhD
Young Suk Lim, MD, PhD
Han Chu Lee, MD, PhD
Young Hwa Chung, MD, PhD
Yung Sang Lee, MD, PhD
Dong Jin Suh, MD, PhD
Publication date
01-03-2009
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-008-0278-3

Other articles of this Issue 3/2009

Annals of Surgical Oncology 3/2009 Go to the issue

Bone and Soft Tissue Sarcomas

Evaluation of 47 Soft Tissue Sarcoma Resection Specimens after Isolated Limb Perfusion with TNF-α and Melphalan: Histologically Characterized Improved Margins Correlate with Absence of Recurrences

Laboratory and Translational Research

Inhibition of Autophagy by 3-MA Enhances the Effect of 5-FU-Induced Apoptosis in Colon Cancer Cells

Healthcare Policy and Outcomes

Disparities in Receipt of Lymph Node Biopsy Among Early-Stage Female Breast Cancer Patients

Laboratory and Translational Research

Tumor-Associated Macrophage Correlated with Angiogenesis and Progression of Mucoepidermoid Carcinoma of Salivary Glands

Endocrine Tumors

5,000 Parathyroid Operations Without Frozen Section or PTH Assays: Measuring Individual Parathyroid Gland Hormone Production in Real Time

Endocrine Tumors

In Vitro Chemoresistance Testing in Well-Differentiated Carcinoid Tumors